1-(1H-苯并[D]咪唑-2-基)-N-甲基甲胺二盐酸盐 | 92809-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-(1H-苯并[D]咪唑-2-基)-N-甲基甲胺二盐酸盐
• 英文名称: (1H-Benzimidazol-2-ylmethyl)methylamine dihydrochloride
• 英文别名: 1-(1H-benzimidazol-2-yl)-N-methylmethanamine;dihydrochloride
• CAS: 92809-96-6
• 化学式: C9H13Cl2N3
• mdl: MFCD07161795
• 分子量: 234.12
• InChiKey: CNFKFLUGCPBOPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.89
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  40.7
• 氢给体数：
  4
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(1H-苯并[D]咪唑-2-基)-N-甲基甲胺二盐酸盐 、 5-溴嘧啶-2,4,6(1h,3h,5h)-三酮 、 乙醇 以65%的产率得到
  参考文献：
  名称：

  GAKHAR, H. K.;SACHDEV, P.;GUPTA, SH. BH., MONATSH. CHEM., 1984, 115, N 6-7, 757-763

  摘要：

  DOI：
• 作为产物：
  描述：

  甲胺 、 2-氯甲基苯并咪唑 在 ice 、 Silica gel 、 methanol-dichloromethane 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 22.0h， 以Silica gel chromatography (step gradient, 10-25% MeOH/CH2Cl2) yielded the title compound (2.5 g, 13%)的产率得到1-(1H-苯并[D]咪唑-2-基)-N-甲基甲胺二盐酸盐
  参考文献：
  名称：

  Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist

  摘要：

  具有以下公式的Vitronectin受体拮抗剂：##STR1## 用于治疗炎症、癌症和心血管疾病，如动脉粥样硬化和再狭窄，以及骨吸收是因素的疾病，如骨质疏松症。

  公开号：

  US05977101A1

文献信息

• HETEROCYCLIC ACETAMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20140315963A1

  公开（公告）日：2014-10-23

  [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

  [问题] 提供了一种作为多巴胺D1受体正变构调节剂（D1 PAM）有用的化合物。 [解决方案] 本发明的发明人已经研究了一种具有多巴胺D1受体正变构调节活性的化合物，该化合物作为用于预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药物组合物的有效成分是有用的，他们因此发现了一种杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，从而完成了本发明。本发明的杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，并且可以用作预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药剂。
• Method for stimulating bone formation
  申请人：SmithKline Beecham Corporation

  公开号：US20020032187A1

  公开（公告）日：2002-03-14

  A method for stimulating bone formation by administering integrin binding compounds which cause the release of osteocalcin from osteoblasts is disclosed.

  通过给予能够引发骨细胞释放骨钙蛋白的整合素结合化合物来刺激骨形成的方法被揭示。
• [EN] METHOD FOR STIMULATING BONE FORMATION<br/>[FR] PROCEDE DE STIMULATION DE LA FORMATION OSSEUSE
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1998015278A1

  公开（公告）日：1998-04-16

  (EN) A method for stimulating bone formation by administering integrin binding compounds which cause the release of osteocalcin from osteoblasts is disclosed.(FR) L'invention concerne un procédé pour stimuler la formation osseuse. Ce procédé consiste à administrer des composés de liaison de l'intégrine, qui provoquent la libération de l'ostéocalcine à partir des ostéoblastes.

  一种通过给予能够引起成骨细胞释放骨钙素的整合素结合化合物来刺激骨形成的方法被揭示。
• Vitronectin receptor antagonist pharmaceuticals
  申请人：——

  公开号：US20040014964A1

  公开（公告）日：2004-01-22

  The present invention describes novel compounds of the formula: (Q) d —L n —C h , useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

  本发明描述了新颖化合物的公式：(Q) d-Ln-Ch，用于癌症的诊断和治疗，患者肿瘤成像方法，以及患者癌症治疗的方法。本发明还提供了新颖化合物，用于监测治疗性血管生成和新血管生成的破坏。本发明进一步提供了新颖化合物，用于成像动脉粥样硬化、再狭窄、心肌缺血和心肌再灌注损伤。本发明还提供了新颖化合物，用于类风湿性关节炎的治疗。这些药物由结合到在血管生成期间上调的受体的靶向基团、可选的连接基团和治疗有效的放射性同位素或诊断有效的可成像基团组成。可成像基团是伽马射线或正电子发射放射性同位素、磁共振成像对比剂、X射线对比剂或超声对比剂。
• Benzodiazepine vitronectin receptor antagonist pharmaceuticals
  申请人：——

  公开号：US20030149262A1

  公开（公告）日：2003-08-07

  The present invention describes novel compounds of the formula: (Q) d —L n —C h , useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

  本发明描述了新型化合物的公式：（Q）d-Ln-Ch，用于癌症的诊断和治疗，用于患者肿瘤成像的方法，以及用于患者癌症治疗的方法。本发明还提供了新型化合物，用于监测治疗性血管生成和新生血管的破坏。药物由结合到在血管生成过程中上调的受体的靶向基团、可选的连接基团和治疗有效的放射性同位素或诊断有效的可成像基团组成。可成像基团是γ射线或正电子发射放射性同位素、磁共振成像对比剂、X射线对比剂或超声对比剂。